Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
1100 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Ovarian Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Ovarian Cancer - Pipeline Review, H2 2014', provides an overview of the Ovarian Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ovarian Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 10 Ovarian Cancer Overview 11 Therapeutics Development 12 Ovarian Cancer - Therapeutics under Development by Companies 14 Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 30 Ovarian Cancer - Pipeline Products Glance 34 Ovarian Cancer - Products under Development by Companies 38 Ovarian Cancer - Products under Investigation by Universities/Institutes 58 Ovarian Cancer - Companies Involved in Therapeutics Development 61 Ovarian Cancer - Therapeutics Assessment 252 Drug Profiles 281 Ovarian Cancer - Recent Pipeline Updates 816 Ovarian Cancer - Dormant Projects 1048 Ovarian Cancer - Discontinued Products 1055 Ovarian Cancer - Product Development Milestones 1057 Appendix 1063
List of Tables Number of Products under Development for Ovarian Cancer, H2 2014 48 Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2014 49 Number of Products under Development by Companies, H2 2014 51 Number of Products under Development by Companies, H2 2014 (Contd..1) 52 Number of Products under Development by Companies, H2 2014 (Contd..2) 53 Number of Products under Development by Companies, H2 2014 (Contd..3) 54 Number of Products under Development by Companies, H2 2014 (Contd..4) 55 Number of Products under Development by Companies, H2 2014 (Contd..5) 56 Number of Products under Development by Companies, H2 2014 (Contd..6) 57 Number of Products under Development by Companies, H2 2014 (Contd..7) 58 Number of Products under Development by Companies, H2 2014 (Contd..8) 59 Number of Products under Development by Companies, H2 2014 (Contd..9) 60 Number of Products under Development by Companies, H2 2014 (Contd..10) 61 Number of Products under Development by Companies, H2 2014 (Contd..11) 62 Number of Products under Development by Companies, H2 2014 (Contd..12) 63 Number of Products under Development by Companies, H2 2014 (Contd..13) 64 Number of Products under Development by Companies, H2 2014 (Contd..14) 65 Number of Products under Investigation by Universities/Institutes, H2 2014 67 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 68 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 69 Comparative Analysis by Late Stage Development, H2 2014 70 Comparative Analysis by Clinical Stage Development, H2 2014 71 Comparative Analysis by Early Stage Development, H2 2014 72 Comparative Analysis by Unknown Stage Development, H2 2014 73 Products under Development by Companies, H2 2014 74 Products under Development by Companies, H2 2014 (Contd..1) 75 Products under Development by Companies, H2 2014 (Contd..2) 76 Products under Development by Companies, H2 2014 (Contd..3) 77 Products under Development by Companies, H2 2014 (Contd..4) 78 Products under Development by Companies, H2 2014 (Contd..5) 79 Products under Development by Companies, H2 2014 (Contd..6) 80 Products under Development by Companies, H2 2014 (Contd..7) 81 Products under Development by Companies, H2 2014 (Contd..8) 82 Products under Development by Companies, H2 2014 (Contd..9) 83 Products under Development by Companies, H2 2014 (Contd..10) 84 Products under Development by Companies, H2 2014 (Contd..11) 85 Products under Development by Companies, H2 2014 (Contd..12) 86 Products under Development by Companies, H2 2014 (Contd..13) 87 Products under Development by Companies, H2 2014 (Contd..14) 88 Products under Development by Companies, H2 2014 (Contd..15) 89 Products under Development by Companies, H2 2014 (Contd..16) 90 Products under Development by Companies, H2 2014 (Contd..17) 91 Products under Development by Companies, H2 2014 (Contd..18) 92 Products under Development by Companies, H2 2014 (Contd..19) 93 Products under Investigation by Universities/Institutes, H2 2014 94 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 95 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 96 Ovarian Cancer - Pipeline by 3-V Biosciences, Inc., H2 2014 97 Ovarian Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 98 Ovarian Cancer - Pipeline by AbbVie Inc., H2 2014 99 Ovarian Cancer - Pipeline by AbGenomics International, Inc., H2 2014 100 Ovarian Cancer - Pipeline by Acceleron Pharma, Inc., H2 2014 101 Ovarian Cancer - Pipeline by Adocia, H2 2014 102 Ovarian Cancer - Pipeline by Aduro BioTech, Inc., H2 2014 103 Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2014 104 Ovarian Cancer - Pipeline by Advantagene, Inc., H2 2014 105 Ovarian Cancer - Pipeline by Advaxis, Inc., H2 2014 106 Ovarian Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2014 107 Ovarian Cancer - Pipeline by Aeterna Zentaris Inc., H2 2014 108 Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 109 Ovarian Cancer - Pipeline by Almac Discovery Ltd., H2 2014 110 Ovarian Cancer - Pipeline by Ambrx, Inc., H2 2014 111 Ovarian Cancer - Pipeline by Amgen Inc., H2 2014 112 Ovarian Cancer - Pipeline by Amorfix Life Sciences Ltd., H2 2014 113 Ovarian Cancer - Pipeline by Angstrom Pharmaceuticals, Inc., H2 2014 114 Ovarian Cancer - Pipeline by AntiCancer, Inc., H2 2014 115 Ovarian Cancer - Pipeline by Aphios Corporation, H2 2014 116 Ovarian Cancer - Pipeline by Aposense Ltd., H2 2014 117 Ovarian Cancer - Pipeline by Aprea AB, H2 2014 118 Ovarian Cancer - Pipeline by arGEN-X BV, H2 2014 119 Ovarian Cancer - Pipeline by Armour Therapeutics Inc., H2 2014 120 Ovarian Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 121 Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 122 Ovarian Cancer - Pipeline by Ascentage Pharma Group Corporation, Ltd., H2 2014 123 Ovarian Cancer - Pipeline by Astellas Pharma Inc., H2 2014 124 Ovarian Cancer - Pipeline by AstraZeneca PLC, H2 2014 125 Ovarian Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2014 126 Ovarian Cancer - Pipeline by AVAX Technologies, Inc., H2 2014 127 Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2014 128 Ovarian Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 129 Ovarian Cancer - Pipeline by Basilea Pharmaceutica AG, H2 2014 130 Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 131 Ovarian Cancer - Pipeline by BioCancell Therapeutics, Inc., H2 2014 132 Ovarian Cancer - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 133 Ovarian Cancer - Pipeline by BioMoti Limited, H2 2014 134 Ovarian Cancer - Pipeline by Bionomics Limited, H2 2014 135 Ovarian Cancer - Pipeline by Bioo Therapeutics, H2 2014 136 Ovarian Cancer - Pipeline by BiOrion Technologies B.V., H2 2014 137 Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2014 138 Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 139 Ovarian Cancer - Pipeline by Bolder Biotechnology, Inc., H2 2014 140 Ovarian Cancer - Pipeline by Boston Biomedical, Inc., H2 2014 141 Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2014 142 Ovarian Cancer - Pipeline by CanBas Co., Ltd., H2 2014 143 Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc., H2 2014 144 Ovarian Cancer - Pipeline by Cavion LLC, H2 2014 145 Ovarian Cancer - Pipeline by Celgene Corporation, H2 2014 146 Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 147 Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2014 148 Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2014 149 Ovarian Cancer - Pipeline by Chikujee Therapeutics, H2 2014 150 Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 151 Ovarian Cancer - Pipeline by Cold Genesys, Inc., H2 2014 152 Ovarian Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 153 Ovarian Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2014 154 Ovarian Cancer - Pipeline by CritiTech, Inc., H2 2014 155 Ovarian Cancer - Pipeline by CTI BioPharma Corp., H2 2014 156 Ovarian Cancer - Pipeline by Curis, Inc., H2 2014 157 Ovarian Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2014 158 Ovarian Cancer - Pipeline by CytRx Corporation, H2 2014 159 Ovarian Cancer - Pipeline by CZ BioMed Corp, H2 2014 160 Ovarian Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 161 Ovarian Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 162 Ovarian Cancer - Pipeline by DEKK-TEC, Inc., H2 2014 163 Ovarian Cancer - Pipeline by Dendreon Corporation, H2 2014 164 Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2014 165 Ovarian Cancer - Pipeline by Endocyte, Inc., H2 2014 166 Ovarian Cancer - Pipeline by Erytech Pharma SA, H2 2014 167 Ovarian Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 168 Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 169 Ovarian Cancer - Pipeline by Formula Pharmaceuticals, Inc., H2 2014 170 Ovarian Cancer - Pipeline by Fujifilm Corporation, H2 2014 171 Ovarian Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 172 Ovarian Cancer - Pipeline by Galileo Research s.r.l., H2 2014 173 Ovarian Cancer - Pipeline by GamaMabs Pharma S.A., H2 2014 174 Ovarian Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 175 Ovarian Cancer - Pipeline by Genentech, Inc., H2 2014 176 Ovarian Cancer - Pipeline by Generex Biotechnology Corporation, H2 2014 177 Ovarian Cancer - Pipeline by Genmab A/S, H2 2014 178 Ovarian Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 179 Ovarian Cancer - Pipeline by GlycoNex Inc., H2 2014 180 Ovarian Cancer - Pipeline by GP Pharm, S.A., H2 2014 181 Ovarian Cancer - Pipeline by Gradalis Inc., H2 2014 182 Ovarian Cancer - Pipeline by Heat Biologics, Inc., H2 2014 183 Ovarian Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2014 184 Ovarian Cancer - Pipeline by Huabo Biopharm Co., Ltd., H2 2014 185 Ovarian Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 186 Ovarian Cancer - Pipeline by IMMD Inc., H2 2014 187 Ovarian Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2014 188 Ovarian Cancer - Pipeline by Immunomedics, Inc., H2 2014 189 Ovarian Cancer - Pipeline by Immunovaccine, Inc., H2 2014 190 Ovarian Cancer - Pipeline by Immunovative Therapies, Ltd., H2 2014 191 Ovarian Cancer - Pipeline by Innate Pharma SA, H2 2014 192 Ovarian Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 193 Ovarian Cancer - Pipeline by INSYS Therapeutics, Inc., H2 2014 194 Ovarian Cancer - Pipeline by ISA Pharmaceuticals B.V., H2 2014 195 Ovarian Cancer - Pipeline by iTeos Therapeutics SA, H2 2014 196 Ovarian Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2014 197 Ovarian Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 198 Ovarian Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 199 Ovarian Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 200 Ovarian Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2014 201 Ovarian Cancer - Pipeline by Medestea Research & Production S.p.A., H2 2014 202 Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2014 203 Ovarian Cancer - Pipeline by MEI Pharma, Inc., H2 2014 204 Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2014 205 Ovarian Cancer - Pipeline by Merck KGaA, H2 2014 206 Ovarian Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2014 207 Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 208 Ovarian Cancer - Pipeline by Mission Therapeutics Ltd, H2 2014 209 Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2014 210 Ovarian Cancer - Pipeline by Morphotek, Inc., H2 2014 211 Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2014 212 Ovarian Cancer - Pipeline by Nektar Therapeutics, H2 2014 213 Ovarian Cancer - Pipeline by Nemucore Medical Innovations, Inc., H2 2014 214 Ovarian Cancer - Pipeline by Neopharm Ltd., H2 2014 215 Ovarian Cancer - Pipeline by Neotropix, Inc., H2 2014 216 Ovarian Cancer - Pipeline by Nerviano Medical Sciences, H2 2014 217 Ovarian Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 218 Ovarian Cancer - Pipeline by Novartis AG, H2 2014 219 Ovarian Cancer - Pipeline by Novogen Limited, H2 2014 220 Ovarian Cancer - Pipeline by NuCana BioMed Limited, H2 2014 221 Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 222 Ovarian Cancer - Pipeline by Ohr Pharmaceutical Inc., H2 2014 223 Ovarian Cancer - Pipeline by Omeros Corporation, H2 2014 224 Ovarian Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 225 Ovarian Cancer - Pipeline by Oncodesign SA, H2 2014 226 Ovarian Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 227 Ovarian Cancer - Pipeline by OncoHoldings, Inc., H2 2014 228 Ovarian Cancer - Pipeline by Oncolix, Inc., H2 2014 229 Ovarian Cancer - Pipeline by Oncology Research International Limited, H2 2014 230 Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 231 Ovarian Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2014 232 Ovarian Cancer - Pipeline by Oncos Therapeutics Ltd., H2 2014 233 Ovarian Cancer - Pipeline by Oncothyreon Inc., H2 2014 234 Ovarian Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 235 Ovarian Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 236 Ovarian Cancer - Pipeline by Optimum Therapeutics, LLC, H2 2014 237 Ovarian Cancer - Pipeline by ORCA Therapeutics B.V., H2 2014 238 Ovarian Cancer - Pipeline by OSE Pharma SA, H2 2014 239 Ovarian Cancer - Pipeline by Oxford BioTherapeutics Ltd, H2 2014 240 Ovarian Cancer - Pipeline by OXiGENE, Inc., H2 2014 241 Ovarian Cancer - Pipeline by Panacela Labs, Inc., H2 2014 242 Ovarian Cancer - Pipeline by Pantarhei Bioscience BV, H2 2014 243 Ovarian Cancer - Pipeline by Pfizer Inc., H2 2014 244 Ovarian Cancer - Pipeline by Pharma Mar, S.A., H2 2014 245 Ovarian Cancer - Pipeline by Pharmicell Co., Ltd., H2 2014 246 Ovarian Cancer - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H2 2014 247 Ovarian Cancer - Pipeline by Polaris Group, H2 2014 248 Ovarian Cancer - Pipeline by Pono Pharma, H2 2014 249 Ovarian Cancer - Pipeline by Precision Biologics, Inc., H2 2014 250 Ovarian Cancer - Pipeline by Qu Biologics Inc., H2 2014 251 Ovarian Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 252 Ovarian Cancer - Pipeline by Quintessence Biosciences, Inc., H2 2014 253 Ovarian Cancer - Pipeline by RAPID Pharmaceuticals AG, H2 2014 254 Ovarian Cancer - Pipeline by Recepta Biopharma S.A., H2 2014 255 Ovarian Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 256 Ovarian Cancer - Pipeline by Rosetta Genomics, Ltd., H2 2014 257 Ovarian Cancer - Pipeline by Sanofi, H2 2014 258 Ovarian Cancer - Pipeline by Santaris Pharma A/S, H2 2014 259 Ovarian Cancer - Pipeline by Scancell Holdings Plc, H2 2014 260 Ovarian Cancer - Pipeline by Sellas Inc., H2 2014 261 Ovarian Cancer - Pipeline by SentoClone International AB, H2 2014 262 Ovarian Cancer - Pipeline by Serina Therapeutics, Inc., H2 2014 263 Ovarian Cancer - Pipeline by Soricimed Biopharma Inc., H2 2014 264 Ovarian Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 265 Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 266 Ovarian Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H2 2014 267 Ovarian Cancer - Pipeline by Supratek Pharma Inc., H2 2014 268 Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 269 Ovarian Cancer - Pipeline by Tactic Pharma, LLC, H2 2014 270 Ovarian Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 271 Ovarian Cancer - Pipeline by TapImmune Inc., H2 2014 272 Ovarian Cancer - Pipeline by Telik, Inc., H2 2014 273 Ovarian Cancer - Pipeline by Tesaro, Inc., H2 2014 274 Ovarian Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H2 2014 275 Ovarian Cancer - Pipeline by Trojantec ltd., H2 2014 276 Ovarian Cancer - Pipeline by TVAX Biomedical, Inc., H2 2014 277 Ovarian Cancer - Pipeline by ValiRx Plc, H2 2014 278 Ovarian Cancer - Pipeline by Vascular Biogenics Ltd., H2 2014 279 Ovarian Cancer - Pipeline by Vaxeal Holding SA, H2 2014 280 Ovarian Cancer - Pipeline by Verastem, Inc., H2 2014 281 Ovarian Cancer - Pipeline by ViraTherapeutics GmbH, H2 2014 282 Ovarian Cancer - Pipeline by Viventia Biotechnologies Inc., H2 2014 283 Ovarian Cancer - Pipeline by Welichem Biotech Inc., H2 2014 284 Ovarian Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H2 2014 285 Ovarian Cancer - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 286 Ovarian Cancer - Pipeline by Zymeworks Inc., H2 2014 287 Assessment by Monotherapy Products, H2 2014 288 Assessment by Combination Products, H2 2014 289 Number of Products by Stage and Target, H2 2014 291 Number of Products by Stage and Mechanism of Action, H2 2014 305 Number of Products by Stage and Route of Administration, H2 2014 314 Number of Products by Stage and Molecule Type, H2 2014 316 Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2014 852 Ovarian Cancer - Dormant Projects, H2 2014 1084 Ovarian Cancer - Discontinued Products, H2 2014 1091
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.